Closed-loop Control of Targeted Ultrasound Drug Delivery Across the Blood-brain/tumor Barriers in a Rat Glioma Model

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2017 Nov 15

PMID 29133392

Citations 114

Authors

Tao Sun

Yongzhi Zhang

Chanikarn Power

Phillip M Alexander

Jonathan T Sutton

Muna Aryal

Natalia Vykhodtseva

Eric L Miller

Nathan J McDannold

Affiliations

Soon will be listed here.

Abstract

Cavitation-facilitated microbubble-mediated focused ultrasound therapy is a promising method of drug delivery across the blood-brain barrier (BBB) for treating many neurological disorders. Unlike ultrasound thermal therapies, during which magnetic resonance thermometry can serve as a reliable treatment control modality, real-time control of modulated BBB disruption with undetectable vascular damage remains a challenge. Here a closed-loop cavitation controlling paradigm that sustains stable cavitation while suppressing inertial cavitation behavior was designed and validated using a dual-transducer system operating at the clinically relevant ultrasound frequency of 274.3 kHz. Tests in the normal brain and in the F98 glioma model in vivo demonstrated that this controller enables reliable and damage-free delivery of a predetermined amount of the chemotherapeutic drug (liposomal doxorubicin) into the brain. The maximum concentration level of delivered doxorubicin exceeded levels previously shown (using uncontrolled sonication) to induce tumor regression and improve survival in rat glioma. These results confirmed the ability of the controller to modulate the drug delivery dosage within a therapeutically effective range, while improving safety control. It can be readily implemented clinically and potentially applied to other cavitation-enhanced ultrasound therapies.

Citing Articles

MRI-guided focused ultrasound for treating Parkinson's disease with human mesenchymal stem cells.

Wu S, Tsai C, Mir A, Hynynen K Sci Rep. 2025; 15(1):2029.

PMID: 39815002 PMC: 11735764. DOI: 10.1038/s41598-025-85811-8.

Drug Release via Ultrasound-Activated Nanocarriers for Cancer Treatment: A Review.

Al Refaai K, AlSawaftah N, Abuwatfa W, Husseini G Pharmaceutics. 2024; 16(11).

PMID: 39598507 PMC: 11597164. DOI: 10.3390/pharmaceutics16111383.

Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy.

Norollahi S, Yousefi B, Nejatifar F, Yousefzadeh-Chabok S, Rashidy-Pour A, Samadani A J Egypt Natl Canc Inst. 2024; 36(1):33.

PMID: 39465481 DOI: 10.1186/s43046-024-00240-4.

Investigation of Sonication Parameters for Large-Volume Focused Ultrasound-Mediated Blood-Brain Barrier Permeability Enhancement Using a Clinical-Prototype Hemispherical Phased Array.

McMahon D, Jones R, Ramdoyal R, Zhuang J, Leavitt D, Hynynen K Pharmaceutics. 2024; 16(10).

PMID: 39458618 PMC: 11510584. DOI: 10.3390/pharmaceutics16101289.

Therapeutic ultrasound: an innovative approach for targeting neurological disorders affecting the basal ganglia.

Singh A, Reynolds J Front Neuroanat. 2024; 18:1469250.

PMID: 39417047 PMC: 11480080. DOI: 10.3389/fnana.2024.1469250.

References

Leslie T, Ritchie R, Illing R, Ter Haar G, Phillips R, Middleton M . High-intensity focused ultrasound treatment of liver tumours: post-treatment MRI correlates well with intra-operative estimates of treatment volume. Br J Radiol. 2012; 85(1018):1363-70. PMC: 3474034. DOI: 10.1259/bjr/56737365. View

Gruber M, Bader K, Holland C . Cavitation thresholds of contrast agents in an in vitro human clot model exposed to 120-kHz ultrasound. J Acoust Soc Am. 2014; 135(2):646-53. PMC: 3986017. DOI: 10.1121/1.4843175. View

Tsai C, Zhang J, Liao Y, Liu H . Real-time monitoring of focused ultrasound blood-brain barrier opening via subharmonic acoustic emission detection: implementation of confocal dual-frequency piezoelectric transducers. Phys Med Biol. 2016; 61(7):2926-46. DOI: 10.1088/0031-9155/61/7/2926. View

OReilly M, Muller A, Hynynen K . Ultrasound insertion loss of rat parietal bone appears to be proportional to animal mass at submegahertz frequencies. Ultrasound Med Biol. 2011; 37(11):1930-7. PMC: 3228246. DOI: 10.1016/j.ultrasmedbio.2011.08.001. View

Sun T, Samiotaki G, Wang S, Acosta C, Chen C, Konofagou E . Acoustic cavitation-based monitoring of the reversibility and permeability of ultrasound-induced blood-brain barrier opening. Phys Med Biol. 2015; 60(23):9079-94. PMC: 4668271. DOI: 10.1088/0031-9155/60/23/9079. View

Elias W, Huss D, Voss T, Loomba J, Khaled M, Zadicario E . A pilot study of focused ultrasound thalamotomy for essential tremor. N Engl J Med. 2013; 369(7):640-8. DOI: 10.1056/NEJMoa1300962. View

Tung Y, Choi J, Baseri B, Konofagou E . Identifying the inertial cavitation threshold and skull effects in a vessel phantom using focused ultrasound and microbubbles. Ultrasound Med Biol. 2010; 36(5):840-52. PMC: 3968802. DOI: 10.1016/j.ultrasmedbio.2010.02.009. View

Raymond S, Skoch J, Hynynen K, Bacskai B . Multiphoton imaging of ultrasound/Optison mediated cerebrovascular effects in vivo. J Cereb Blood Flow Metab. 2006; 27(2):393-403. DOI: 10.1038/sj.jcbfm.9600336. View

Marquet F, Tung Y, Teichert T, Ferrera V, Konofagou E . Noninvasive, transient and selective blood-brain barrier opening in non-human primates in vivo. PLoS One. 2011; 6(7):e22598. PMC: 3142168. DOI: 10.1371/journal.pone.0022598. View

10.

Mead B, Mastorakos P, Suk J, Klibanov A, Hanes J, Price R . Targeted gene transfer to the brain via the delivery of brain-penetrating DNA nanoparticles with focused ultrasound. J Control Release. 2016; 223:109-117. PMC: 4739627. DOI: 10.1016/j.jconrel.2015.12.034. View

11.

Barth R, Kaur B . Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol. 2009; 94(3):299-312. PMC: 2730996. DOI: 10.1007/s11060-009-9875-7. View

12.

OReilly M, Huang Y, Hynynen K . The impact of standing wave effects on transcranial focused ultrasound disruption of the blood-brain barrier in a rat model. Phys Med Biol. 2010; 55(18):5251-67. PMC: 3207361. DOI: 10.1088/0031-9155/55/18/001. View

13.

McDannold N, Vykhodtseva N, Hynynen K . Microbubble contrast agent with focused ultrasound to create brain lesions at low power levels: MR imaging and histologic study in rabbits. Radiology. 2006; 241(1):95-106. DOI: 10.1148/radiol.2411051170. View

14.

Chen X, Novak P, Benson Jr D, Webber J, Hennings L, Shafirstein G . An alternating focused ultrasound system for thermal therapy studies in small animals. Med Phys. 2011; 38(4):1877-87. PMC: 3069994. DOI: 10.1118/1.3553405. View

15.

McDannold N, Tempany C, Fennessy F, So M, Rybicki F, Stewart E . Uterine leiomyomas: MR imaging-based thermometry and thermal dosimetry during focused ultrasound thermal ablation. Radiology. 2006; 240(1):263-72. PMC: 1850234. DOI: 10.1148/radiol.2401050717. View

16.

Aryal M, Vykhodtseva N, Zhang Y, McDannold N . Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study. J Control Release. 2015; 204:60-9. PMC: 4385501. DOI: 10.1016/j.jconrel.2015.02.033. View

17.

Bakay L, BALLANTINE Jr H, Hueter T, Sosa D . Ultrasonically produced changes in the blood-brain barrier. AMA Arch Neurol Psychiatry. 1956; 76(5):457-67. DOI: 10.1001/archneurpsyc.1956.02330290001001. View

18.

Aryal M, Arvanitis C, Alexander P, McDannold N . Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system. Adv Drug Deliv Rev. 2014; 72:94-109. PMC: 4041837. DOI: 10.1016/j.addr.2014.01.008. View

19.

Treat L, McDannold N, Zhang Y, Vykhodtseva N, Hynynen K . Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma. Ultrasound Med Biol. 2012; 38(10):1716-25. PMC: 3438387. DOI: 10.1016/j.ultrasmedbio.2012.04.015. View

20.

Arvanitis C, Livingstone M, McDannold N . Combined ultrasound and MR imaging to guide focused ultrasound therapies in the brain. Phys Med Biol. 2013; 58(14):4749-61. PMC: 3955087. DOI: 10.1088/0031-9155/58/14/4749. View